
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Ping An's lung nodule smart reading technology is assessed by LUNA as No. 1 in the World

January 12, 2018 | News

This is the first time that Ping An Technology has won a world record in the medical imaging field



Ping An Technology was ranked as a leader in medical imaging analysis, as its Ping An Yingxiang platform set world records for nodule detection and false positive reduction with reduction with average sensitivity rates of 95.1 percent and 96.8 percent respectively in the authoritative LUNA rankings for medical imaging.

LUNA (LUng Nodule Analysis) is an internationally recognized evaluation system for pulmonary nodule detection and setting the benchmark for all competitors in the field of medical imaging.

The evaluation, held as a form of competition, is being carried out by more than 3,600 professional teams from academic and industrial circles worldwide since 2016.

Each competing team is required to analyze the lung CT samples of nearly 1,000 people and locate the nodules.

It is a difficult task as most of the nodules diameters are smaller than 3mm (the same width as three human hairs.

Screening high risk individuals for lung cancer with low-dose CT scans is now being implemented in the United States and other countries are expected to soon follow suit.

In CT lung cancer screening, millions of scans will need to be analyzed, creating an enormous burden for radiologists.

As a result, it has become necessary to develop intelligent algorithms that are optimized for lung cancer detection.

Leveraging its advantages in the relevant areas, Ping An Technology's medical imaging team proposed an innovative solution to this challenge which integrates robust control theory with advanced AI algorithms including deep learning and transfer learning, achieving excellent results and world-leading status in pulmonary nodule detection, localization and recognition.

The technology is being applied in collaboration with the Shanghai Institute of Respiratory Diseases and several leading Grade III, Class A hospitals.

The team, with strong R&D backing, now provides a wide range of medical AI capabilities to screen for gastric, liver, cervical and thyroid cancer as well as estimate bone age, detect diabetic retinopathy and thorax related diseases.

Ping An Technology also acts as Ping An Group's technology incubator, with strong research, development and application abilities in AI, big data and the cloud.